Literature DB >> 20455053

[Acute upper gastrointestinal bleeding after coronary intervention in acute myocardial infarction].

Stefanie Strobl1, Ina Zuber-Jerger.   

Abstract

HISTORY AND ADMISSION
FINDINGS: A 73-year-old man with NSTEMI (non-ST segment elevation myocardial infarction) underwent coronary angiography and an in-stent restenosis and thrombosis in ramus circumflexus was found. A drug-eluting stent (DES) was implanted. 12 h after intervention during threefold platelet inhibition the patient presented a gastrointestinal bleeding with melena and the hemoglobin level dropped from 15.3 g/dl to 9.7 g/dl. INVESTIGATIONS: Blood tests revealed a considerable elevation of cardiac enzymes, troponin I, leukocytes and C-reactive protein but normal hemoglobin. In coronary angiography, the stent in ramus circumflexus was found to be occluded. Therefore, a percutaneous coronary intervention with implantation of a DES (Taxus) was performed. In gastroscopy, a 2.5-cm necrotic formation resembling a tumor with an oozing bleeding was identified. The bleeding was stopped after injection of adrenaline. Histological evaluation showed no criteria of malignancy. TREATMENT AND COURSE: With high-dose proton pump blocker therapy, calculated Helicobacter pylori eradication with amoxicillin and clarithromycin, and cessation of NSAID (nonsteroidal anti-inflammatory drugs), the hemoglobin level was stable with 9.7 g/dl. No blood transfusion and no interruption of the dual platelet inhibition were necessary. In control gastroscopy, the initial endoscopically malignancy-suspicious formation presented as a small, superficial, healing ulcer.
CONCLUSION: Bleeding complications after stent implantation create a dilemma situation. The risk of a hemorrhagic shock by continuing platelet inhibition therapy and the risk of an acute stent thrombosis with interruption of the platelet inhibition should be carefully calculated considering individual facts and the guidelines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455053     DOI: 10.1007/s00063-010-1044-4

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  14 in total

1.  [Percutaneous coronary interventions (PCI)].

Authors:  Tassilo Bonzel; Raimund Erbel; Christian W Hamm; Benny Levenson; Franz-Josef Neumann; Hans-Jürgen Rupprecht; Ralf Zahn
Journal:  Clin Res Cardiol       Date:  2008-08       Impact factor: 5.460

2.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.

Authors:  Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

3.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.

Authors:  Andrew T L Ong; Angela Hoye; Jiro Aoki; Carlos A G van Mieghem; Gaston A Rodriguez Granillo; Karel Sonnenschein; Evelyn Regar; Eugene P McFadden; Georgios Sianos; Willem J van der Giessen; Peter P T de Jaegere; Pim de Feyter; Ron T van Domburg; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

4.  Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).

Authors:  Elliott M Antman; David A Morrow; Carolyn H McCabe; Frank Jiang; Harvey D White; Keith A A Fox; Divakar Sharma; Paul Chew; Eugene Braunwald
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

5.  Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.

Authors:  Jean-Philippe Collet; Gilles Montalescot; Giancarlo Agnelli; Frans Van de Werf; Enrique P Gurfinkel; Jose López-Sendón; Christopher V Laufenberg; Martin Klutman; Neelam Gowda; Dietrich Gulba
Journal:  Eur Heart J       Date:  2005-06-02       Impact factor: 29.983

6.  Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study.

Authors:  Jesper Hallas; Michael Dall; Alin Andries; Birthe Søgaard Andersen; Claus Aalykke; Jane Møller Hansen; Morten Andersen; Annmarie Touborg Lassen
Journal:  BMJ       Date:  2006-09-19

7.  Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.

Authors:  Jolanta M Siller-Matula; Alexander O Spiel; Irene M Lang; Gerhard Kreiner; Guenter Christ; Bernd Jilma
Journal:  Am Heart J       Date:  2008-11-06       Impact factor: 4.749

8.  Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study.

Authors:  Marcus W S Chin; Gerald Yong; Max K Bulsara; Jamie Rankin; Geoffrey M Forbes
Journal:  Am J Gastroenterol       Date:  2007-09-10       Impact factor: 10.864

9.  Coronary stent occlusion after platelet transfusion: a case series.

Authors:  Alexander D Cornet; Lucas J Klein; A B Johan Groeneveld
Journal:  J Invasive Cardiol       Date:  2007-10       Impact factor: 2.022

10.  Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding.

Authors:  Alan Barkun; Marc Bardou; John K Marshall
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  1 in total

1.  Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy.

Authors:  Gro Egholm; Troels Thim; Morten Madsen; Henrik Toft Sørensen; Jan Bech Pedersen; Svend Eggert Jensen; Lisette Okkels Jensen; Steen Dalby Kristensen; Hans Erik Bøtker; Michael Maeng
Journal:  Endosc Int Open       Date:  2016-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.